UBS Group Has Lowered Expectations for DENTSPLY SIRONA (NASDAQ:XRAY) Stock Price

DENTSPLY SIRONA (NASDAQ:XRAY – Get Free Report) had its target price dropped by stock analysts at UBS Group from $17.00 to $13.00 in a report released on Monday, Benzinga reports. The brokerage presently has a “buy” rating on the medical instruments supplier’s stock. UBS Group‘s price target suggests a potential upside of 51.16% from the company’s current price.

XRAY has been the topic of a number of other reports. Bank of America restated a “buy” rating on shares of DENTSPLY SIRONA in a research note on Friday, November 6th. JPMorgan Chase & Co. lowered their price objective on shares of DENTSPLY SIRONA from $12.00 to $10.00 and set a “neutral” rating for the company in a research report on Friday, November 6th. Barclays upped their price objective on shares of DENTSPLY SIRONA from $9.00 to $11.00 and gave the stock an “underweight” rating in a research report on Monday, August 24th. Barrington Research dropped their price objective on shares of DENTSPLY SIRONA from $15.00 to $13.00 and set an “outperform” rating for the company in a research note on Monday, October 26th. Finally, BMO Capital Markets cut their target price on shares of DENTSPLY SIRONA from $13.00 to $10.00 and set a “market perform” rating on the stock in a research report on Thursday, September 17th. Three research analysts have rated the stock with a Buy rating, seven have given a Hold rating and four have given a Sell rating to the company. According to MarketBeat, DENTSPLY SIRONA presently has a consensus rating of “Reduce” and an average price target of $12.08.

Check Out Our Latest Report on DENTSPLY SIRONA

DENTSPLY SIRONA Price Performance

Shares of XRAY stock opened at $8.60 on Monday. The company has a quick ratio of 1.04, a current ratio of 1.63 and a debt-to-equity ratio of 1.47. DENTSPLY SIRONA has a twelve month low of $8.14 and a twelve month high of $14.76. The company has a market cap of $1.70 billion, a P/E ratio of 6.63, a P/E/G ratio of 1.31 and a beta of 0.87. The business has a fifty day simple moving average of $9.34 and a 200 day simple moving average of $11.16.

DENTSPLY SIRONA (NASDAQ:XRAY – Get Free Report) last released its quarterly earnings data on Thursday, November 5th. The medical instruments supplier reported $0.29 earnings per share for the quarter, missing the consensus estimate of $0.31 by ($0.02). DENTSPLY SIRONA had a negative net margin of 3.38% and a positive return on equity of 20.21%. The business had revenue of $836.00 million during the quarter, compared to analyst estimates of $861.68 million. During the same period last year, the business earned $0.37 earnings per share. The business’s quarterly revenue was down 7.5% compared to the same quarter last year. DENTSPLY SIRONA has set its FY 2026 guidance at 1.200-1.300 EPS. On average, sell-side analysts forecast that DENTSPLY SIRONA will post 1.21 EPS for the current fiscal year.

Institutional Trading of DENTSPLY SIRONA

A number of hedge funds have recently made changes to their positions in XRAY. Allworth Financial LP increased its stake in shares of DENTSPLY SIRONA by 119.7% in the third quarter. Allworth Financial LP now owns 10,579 shares of the medical instruments supplier’s stock valued at $94,000 after buying an additional 5,764 shares during the period. Goldman Sachs Group Inc. boosted its position in DENTSPLY SIRONA by 53.4% during the 3rd quarter. Goldman Sachs Group Inc. now owns 2,827,392 shares of the medical instruments supplier’s stock worth $25,051,000 after buying an additional 983,806 shares during the period. CSM Advisors LLC boosted its position in DENTSPLY SIRONA by 111.2% during the 3rd quarter. CSM Advisors LLC now owns 80,235 shares of the medical instruments supplier’s stock worth $711,000 after buying an additional 42,245 shares during the period. Cetera Investment Advisers boosted its position in DENTSPLY SIRONA by 16.0% during the 3rd quarter. Cetera Investment Advisers now owns 36,749 shares of the medical instruments supplier’s stock worth $326,000 after buying an additional 5,081 shares during the period. Finally, Bleakley Financial Group LLC boosted its position in DENTSPLY SIRONA by 57.1% during the 3rd quarter. Bleakley Financial Group LLC now owns 35,451 shares of the medical instruments supplier’s stock worth $314,000 after buying an additional 12,891 shares during the period. 95.70% of the stock is owned by institutional investors and hedge funds.

About DENTSPLY SIRONA

(Get Free Report)

DENTSPLY SIRONA Inc. develops, manufactures and markets products and technologies for dental professionals. Its portfolio includes dental equipment and imaging systems, digital dentistry and CAD/CAM solutions, dental implants, endodontic and restorative products, and supplies used in preventive care. The company serves dental practices, laboratories and other customers around the world. Its products support a range of clinical activities, including diagnosis, treatment planning, restorative dentistry and oral hygiene.

Further Reading

Analyst Recommendations for DENTSPLY SIRONA (NASDAQ:XRAY)

Receive News & Ratings for DENTSPLY SIRONA Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DENTSPLY SIRONA and related companies with MarketBeat.com's FREE daily email newsletter.